Problems and controversies in the management of hematogenous candidiasis

Clinical Infectious Diseases

Volumn 22, Issue SUPPL. 2, 1996, Pages

  Uzun, Omrum ^a   Anaissie, Elias J ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; COLONY STIMULATING FACTOR RECEPTOR; FLUCONAZOLE; FLUCYTOSINE;

ANTIFUNGAL ACTIVITY; CANDIDIASIS; CENTRAL VENOUS CATHETER; CONFERENCE PAPER; DISEASE TRANSMISSION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; HUMAN; HUMAN CELL; NEUTROPENIA; PRIORITY JOURNAL;

EID: 0030055629     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.supplement_2.s95     Document Type: Conference Paper

References (62)

1. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-5.
2. Karabinis A, Hill C, Leclercq B, Tancrède C, Baume D, Andremont A. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988;26:429-32.
3. Bross J, Talbot GH, Maislin G, Hurwitz S, Strom BL. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 1989;87:614-20.
4. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989;149:2349-53.
5. Verfaillie C, Weisdorf D, Haake R, Hostetter M, Ramsay NKC, McGlave P. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991;8:177-84.
6. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991;164:731-40.
7. Richet HM, Andremont A, Tancrede C, Pico JL, Jarvis WR. Risk factors for candidemia in patients with acute lymphocyte leukemia. Rev Infect Dis 1991;13:211-5.
8. Weese-Mayer DE, Fondriest DW, Brouillette RT, Shulman ST. Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study. Pediatr Infect Dis J 1987;6:190-6.
9. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-21.
10. Anaissie EJ, Abi-Said D, Uzun O, et al. Prognostic factors for hematogenous candidiasis in cancer patients, [abstract no J27]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
11. Anaissie EJ, Karyotakis NC, Hachem R, Dignani MC, Rex JH, Paetznick V. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis 1994;170:384-9.
12. Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother 1993;37:2449-53.
13. Rex JH, Pfaller MA, Barry AL, Webb CD for the NIAID Mycoses Study Group and the Candidemia Study Group. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother 1995;39:40-4.
14. Bindschadler DD, Bennett JE. A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis 1969;120:427-36.
15. Bodey GP. Candidiasis in cancer patients. Am J Med 1984;77 (suppl 4D):13-9.
16. Meunier F. Fungal infections in cancer patients. Cancer Invest 1991;9:151-8.
17. Anaissie E, Solomkin JS. Fungal Infection. In: Wilmore DW, Brennan MF, Harken AH, Holcroft JW, Meakins JL, eds. Care of the surgical patient. Vol 2. New York: Scientific American, 1994:1-19.
18. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
19. Walsh TJ, Aoki S, Mechinaud F, et al. Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. J Infect Dis 1990;161:755-60.
20. Van't Wout JW, Mattie H, van Furth R. A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections. J Antimicrob Chemother 1988;21:665-72.
21. Kujath P, Lerch K. Secondary mycosis in surgery: treatment with fluconazole. Infection 1989;17:111-7.
22. Nolla-Salas J, León C, Torres-Rodríguez JM, Martín E, Sitges-Serra A. Treatment of candidemia in critically ill surgical patients with intravenous fluconazole. Clin Infect Dis 1992;14:952-4.
23. Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A. Treatment of Candida albicans fungemia with fluconazole. J Infect 1993;26:133-46.
24. Ikemoto H. A clinical study of fluconazole for the treatment of deep mycoses. Diagn Microbiol Infect Dis 1989;12(suppl 4):239S-47S.
25. Anaissie E, Pinczowski H, Elting L, Kontoyiannis D, Vartivarian S, Bodey GP. Response of fluconazole-treated cancer (Ca) patients (pts) with candidemia compared with that of pts treated with amphotericin (AmB): a prospective matched pairs study [abstract no 6301]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (Anaheim, CA). Washington, DC: American Society for Microbiology, 1992.
26. Nguyen MH, Peacock JE, Tanner MD, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995;155:2429-35.
27. Kujath P, Lerch K, Kochendörfer P, Boos C. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection 1993;21:376-81.
28. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
29. Anaissie EJ, Darwiche R, Mera J, Gentry L, Abi-Said D, Bodey GP. A prospective randomized multicenter study comparing fluconazole to amphotericin B for nosocomial candidiasis [abstract no 808]. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1993.
30. Morace G, Manzara S, Dettori G. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B, and ketoconazole. Chemotherapy 1991;37:23-31.
31. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 1994;38:1422-4.
32. Odds FC. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole and miconazole among pathogenic fungi in vitro. Antimicrob Agents Chemother 1982;21:763-70.
33. Rabinovich S, Shaw BD, Bryant T, Donta ST. Effect of 5-fluorocytosine and amphotericin B on Candida albicans infection in mice. J Infect Dis 1974;130:28-31.
34. Mary C, Goudard M, Blancard A, Quilici M, Regli P. Effet synergique entre 5-flurocytosine et les dérivés imidazolés vis-à-vis de souche de levures résistantes a la 5-flurocytosine. Ann Biol Clin (Paris) 1989;47:546-9.
35. Blinkhorn RJ, Adelstein D, Spagnuolo PJ. Emergence of a new opportunistic pathogen, Candida lusitaniae. J Clin Microbiol 1989;27:236-40.
36. Dignani MC, Karyotakis NC, Paetznick V, Anaissie E. Candida lusitaniae (CL): in vitro susceptibility and in vivo correlation in experimental murine candidiasis [abstract A23]. In: Program and abstracts of the Conference on Candida and Candidiasis: Biology, Pathogenesis and Management (Baltimore). Washington, DC: American Society for Microbiology, 1993.
37. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37:1847-9.
38. Martin E, Maier F, Bhakdi S. Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob Agents Chemother 1994;38:1331-8.
39. Petrou MA, Rogers TR. Interactions in vitro between polyenes and imidazoles against yeasts. J Antimicrob Chemother 1991;27:491-506.
40. Anaissie EJ, Hachem R, Karyotakis NC, et al. Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis. Antimicrob Agents Chemother 1994;38:2541-4.
41. Sugar AM, Hitchcock CA, Troke PF, Picard M. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother 1995;39:598-601.
42. Eppes SC, Troutman JL, Gutman LT. Outcome of treatment of candidemia in children whose central catheters were removed or retained. Pediatr Infect Dis J 1989;8:99-104.
43. Dato VM, Dajani AS. Candidemia in children with central venous catheters: role of catheter removal and amphotericin B therapy. Pediatr Infect Dis J 1990;9:309-14.
44. Lecciones JA, Lee JW, Navarro EE, et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992;14:875-83.
45. Rex JH, Bennett JE, Sugar AM, et al. Fluconazole (FLU) vs. amphotericin B (AMB) for treatment of candidemia: results of a randomized, multicenter trial [abstract no 805]. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1993.
46. Walsh TJ, Merz WG. Pathologic features in the human alimentary tract associated with the invasiveness of Candida tropicalis. Am J Clin Pathol 1986;85:498-502.
47. Martino P, Girmenia C, Venditti M, et al. Candida colonization and systemic infection in neutropenic patients. A retrospective study. Cancer 1989;64:2030-4.
48. Martino P, Girmenia C, Micozzi A, De Bernardis F, Boccanera M, Cassone A. Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients. Eur J Clin Microbiol Infect Dis 1994;13:797-804.
49. Pappu-Katikaneni LD, Rao KPP, Banister E. Gastrointestinal colonization with yeast species and Candida septicemia in very low birth weight infants. Mycoses 1990;33:20-3.
50. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220:751-8.
51. Groeger JS, Lucas AB, Thaler HT, et al. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 1993;119:1168-74.
52. Girmenia C, De Bernardis F, Cassone A, Martino P. C. parapsilosis fungemia and fungal biotyping in patients with hematologic malignancies [abstract no 1181]. In: Program and abstracts of the 8th International Symposium on Infections in the Immunocompromised Host (Davos, Switzerland). Immunocompromised Host Society, 1994.
53. Anaissie E, Paetznick V, Proffitt R, Adler-Moore J, Bodey GP. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis 1991;10:665-8.
54. Pahls S, Schaffner A. Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis. J Infect Dis 1994;169:1057-61.
55. Anaissie E, White M, Uzun O, et al. Amphotericin B Lipid Complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial [abstract no LM21]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
56. Nemunaitis J, Meyers JD, Buckner CD, et al. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 1991;78:907-13.
57. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. Eur J Clin Microbiol Infect Dis 1994;13 (suppl 2):S18-22.
58. Ruthe RC, Andersen BR, Cunningham BL, Epstein RB. Efficacy of granulocyte transfusions in the control of systemic candidiasis in the leukopenic host. Blood 1978;52:493-8.
59. Strauss RG. Therapeutic granulocyte transfusions in 1993. Blood 1993;81:1675-8.
60. Caspar CB, Seger RA, Burger J, Gmur J. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood 1993;81:2866-71.
61. Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993;81:1883-8.
62. Feldman E, Hester J, Vartivarian S, O'Brien S, Bodey GP, Freireich E. The use of granulocyte-colony stimulating factor (G-CSF) enhanced granulocyte transfusions from normal donors in patients (pts) with neutropenia-related fungal infections [abstract no. 711]. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1993.